NurExone Biologic Inc.
NRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -38.58% | -8.12% | -8.97% | 41.21% | 55.45% |
| Total Depreciation and Amortization | 157.58% | 58.06% | 226.67% | 250.00% | 450.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.23% | 102.35% | 143.84% | -31.77% | -70.37% |
| Change in Net Operating Assets | -23,175.00% | -227.00% | -209.22% | -409.68% | -98.31% |
| Cash from Operations | -66.20% | -22.25% | -19.69% | -2.28% | 23.57% |
| Capital Expenditure | -440.83% | -1,325.53% | -545.61% | -197.12% | -130.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -139.13% | -- | 135.14% | 162.16% | 162.16% |
| Cash from Investing | -578.35% | -1,297.87% | -277.66% | -102.84% | -8.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -7.14% | -55.00% | -183.33% | -21.74% | -86.67% |
| Issuance of Common Stock | 448.08% | 494.07% | 8,200.00% | 133.33% | -57.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -25.26% | 203.53% | -38.84% | -40.76% | -94.48% |
| Cash from Financing | 419.26% | 407.98% | 219.76% | 48.23% | -73.64% |
| Foreign Exchange rate Adjustments | -981.25% | 900.00% | 166.67% | 96.97% | 85.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 108.27% | 168.73% | 197.85% | 6,311.54% | -871.89% |